Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Compass Therapeutics

Compass Therapeutics
2015 FOUNDED
PRIVATE STATUS
51-60 EMPLOYEES
Series A LATEST DEAL TYPE
$132M LATEST DEAL AMOUNT
18 INVESTORS
Description

Operator of a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics. The company has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabsTM and common light-chain based multispecific platforms to empirically identify combinations and multispecifics with optimized activity.

Formerly Known As
Kairos Biologics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Primary Office
  • 245 First Street
  • 3rd Floor
  • Cambridge, MA 02142
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Compass Therapeutics’s full profile, request a free trial.

Compass Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series A) 12-Jul-2018 $132M 00000 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 00000 Completed Clinical Trials - Phase 1
2. Early Stage VC (Series A2) 06-Sep-2016 $50M $170M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A1) 02-Jun-2015 $120M $120M Completed Clinical Trials - Phase 1
To view this company’s complete deal history including valuation and funding, request access »

Compass Therapeutics Competitors (57)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sutro Biopharma Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
0-0000 Failed Transaction (M&A) Vienna, Austria 00 000.00 000000&0
0000000 0000000000 Formerly VC-backed Heidelberg, Germany 000 00000 00000000000 00000
0000000 00000000 Formerly VC-backed Bothell, WA 0000 00000 000000000 00000
000000 00000000000 Failed Transaction (M&A) Cambridge, MA 000 00000 000000&0
To view this company’s complete list of competitors, request access »

Compass Therapeutics Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Biomatics Capital Venture Capital Minority 000 0000 000000 0
BioMed Realty Real Estate Minority 000 0000 000000 0
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Cowen Private Investments Other Minority 000 0000 000000 0
Polaris Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 18 investors. Get the full list »

Compass Therapeutics Executive Team (11)

Name Title Board
Seat
Contact
Info
Thomas Schuetz Ph.D Co-Founder, Chief Executive Officer & Board Member
Vered Bisker-Leib Ph.D Chief Business Officer & Head of Operations
Michael Schmidt Ph.D Senior Vice President & Head of Research
Greg Zarbis-Papastoitsis Ph.D Senior Vice President, Process and Manufacturing
Steven Tregay Ph.D Co-Founder & Chairman

5 Former Executives

You’re viewing 5 of 11 executives. Get the full list »

Compass Therapeutics Board Members (11)

Name Representing Role Since Contact
Info
Ben Auspitz F-Prime Capital Partners Board Member 000 0000
Bruce Steel Self Board Observer 000 0000
Carl Gordon Ph.D OrbiMed Board Member 000 0000
Julie Sunderland Biomatics Capital Board Member 000 0000
Philip Ferneau JD Borealis Ventures Board Member 000 0000

2 Former Board Members

You’re viewing 5 of 11 board members. Get the full list »